Tools for Practice Outils pour la pratique

#229 Antispasmodics and peppermint oil: Old news or a breath of fresh air in managing Irritable Bowel Syndrome

Are antispasmodics (including peppermint oil) effective in treating irritable bowel syndrome symptoms?

Approximately 60% of patients report overall symptom or abdominal pain "improvement" on antispasmodics (including peppermint oil), compared to ~30-50% on placebo, with numbers needs to treat of 3-8.  Compared to placebo, adverse events occur for an additional 1 in 20 with antispasmodics and 1 in 11 on peppermint oil.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

3 Systematic Reviews:
  • 29 randomized controlled trials (RCTs), 2333 patients, various antispasmodics, including peppermint oil.1 Patient reported outcomes after 1 week to 6 months:
    • Overall "symptom improvement": 57% versus 39% placebo; number needed to treat (NNT)=6.
    • Abdominal pain "improvement": 58% versus 46% placebo; NNT=8
  • Older systematic review (13 RCTs, 1379 patients). Outcomes at 2 weeks-6 months similar.2 Adverse events (dry mouth, dizziness, blurred vision reported):
    • 14% versus 9% placebo; number needed to harm (NNH)=20.
  • Systematic review of peppermint oil alone (9 RCTs, 726 patients, 2-12 weeks duration).3
    • Overall "symptom improvement": 69 versus 31% placebo; NNT=3.
    • Abdominal pain "improvement": 57% versus 27% placebo; NNT=4.
    • Overall adverse events (including heartburn, dry mouth, peppermint smell/taste):
      • 22% versus 13% placebo; NNH=11.
Newest RCTs:
  • 712 patients randomized to hyoscine, hyoscine + acetaminophen, acetaminophen, or placebo for four weeks.4 Paper translated by TFP authors.
    • "Slight" or "significant" symptom improvement: hyoscine + acetaminophen=81%, hyoscine=76%, acetaminophen=72%, placebo=64%;
      • Hyoscine groups statistically better than placebo.
    • Adverse events: 5% overall.
  • 427 patients given pinaverium 50mg or placebo TID.5 After 4 weeks:
    • >30% improvement in abdominal pain: 62% versus 30% placebo; NNT=3.
  • 72 patients given peppermint oil tablets or placebo.6 After 4 weeks:
    • Mean reduction 4-point symptom score: ~1.2 peppermint oil versus 0.7 placebo.
Limitations: small studies,1,2 short durations,1 multiple/incomplete outcomes reported1,4, conflicts of interest/industry funding3,6, use of non-validated scales.6 Context:
  • Large placebo response often seen in IBS studies.7
  • Guidelines recommend considering antispasmodics8,9 or peppermint oil8 in IBS patients.
  • Antispasmodics in Canada include hyoscine, pinaverium, trimebutine, dicycloverine, peppermint oil.
    • Cost varies significantly
      • Peppermint oil ranges ~$60 to $360 for 3 months.10

Latest Tools for Practice
Derniers outils pour la pratique

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

#364 Facing the Evidence in Acne, Part II: Oral Antibiotics

How effective are oral antibiotics in treating acne of at least mild-moderate severity?
Read Lire 0.25 credits available Crédits disponibles

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Amol Bhargava MD MSc
  • Michael R Kolber MD CCFP MSc

1. Ruepert L, Quartero AO, de Wit NJ, et al. Cochrane Database Syst Rev. 2011; 8:CD003460.

2. Ford AC, Talley NJ, Spiegel BMR, et al. BMJ. 2008; 337:a2313.

3. Khanna R, MacDonald JK, Levesque BG. J Clin Gastroenterol. 2014; 48(6): 505-12.

4. Schafer VE, Ewe K. Fortschr. Med. 1990; 25: 488-92.

5. Zhang L, Lai Y, Lu W, et al. Clin Gastroenterol Hepatol. 2015; 13:1285-92.

6. Cash BD, Epstein MS, Shah SM. Dig Dis Sci. 2016; 61:560-71.

7. Kaptchuk TJ, Friedlander E, Kelley JM, et al. PLOS One. 2010; 5(12):e15591.

8. Ford AC, Moayyedi P, Lacy BE, et al. Am J Gastroenterol. 2014; 109:S2 - S26

9. National Institute for Health and Care Excellence (NICE). 2017. Irritable bowel syndrome in adults: diagnosis and management. CG61.

10. 2018. Accessed Sept 3, 2018.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.